Published in Ann Oncol on March 07, 2014
Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer | NCT05250336
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol (2015) 1.76
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One (2014) 1.64
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol (2016) 1.54
Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45
The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. J Transl Med (2015) 1.41
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016) 1.33
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A (2015) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol (2015) 1.08
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res (2015) 1.01
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget (2016) 1.00
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 0.99
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res (2015) 0.98
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med (2014) 0.96
Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) (2016) 0.95
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology (2014) 0.93
Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res (2015) 0.93
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget (2015) 0.93
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer (2015) 0.88
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget (2016) 0.88
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol (2015) 0.86
The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol (2016) 0.85
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat (2014) 0.85
Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85
Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist (2016) 0.84
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.84
The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther (2016) 0.84
Cancer immunoprevention. Curr Opin Immunol (2016) 0.83
Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Res Treat (2016) 0.83
Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer (2015) 0.82
Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol (2015) 0.82
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res (2016) 0.81
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res (2015) 0.81
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel) (2016) 0.81
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist (2016) 0.80
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat (2016) 0.80
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. Oncoimmunology (2015) 0.80
Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. Mod Pathol (2015) 0.80
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol (2016) 0.80
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer (2016) 0.79
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunol Res (2016) 0.79
Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget (2016) 0.79
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. PLoS Med (2016) 0.78
Immunoscoring breast cancer: TILs remember what they target. Ann Oncol (2014) 0.78
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget (2016) 0.78
Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med (2016) 0.78
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. Int J Clin Oncol (2015) 0.78
Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Front Immunol (2014) 0.78
Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. J Thorac Dis (2016) 0.78
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. Mol Cell Oncol (2015) 0.77
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol (2016) 0.77
Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. PLoS One (2016) 0.77
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget (2015) 0.77
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open (2017) 0.76
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother (2016) 0.76
Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer (2016) 0.76
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat (2016) 0.76
Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol (2016) 0.76
Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget (2016) 0.76
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res (2016) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget (2016) 0.75
Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Breast Cancer (2016) 0.75
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. Sci Rep (2017) 0.75
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One (2017) 0.75
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget (2015) 0.75
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med (2016) 0.75
Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. Sci Rep (2016) 0.75
Predictive factors of tumor immune microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci (2016) 0.75
Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic Approach. Biomed Eng Comput Biol (2016) 0.75
The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. PLoS One (2016) 0.75
Comparison of Tumour-infiltrating Lymphocytes between Primary and Metastatic Tumours in Breast Cancer Patients. Cancer Sci (2016) 0.75
Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. Oncotarget (2017) 0.75
A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. Ecancermedicalscience (2016) 0.75
Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer. Am J Transl Res (2017) 0.75
Immune DNA signature of T-cell infiltration in breast tumor exomes. Sci Rep (2016) 0.75
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer (2015) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. J Carcinog Mutagen (2014) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS One (2017) 0.75
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget (2016) 0.75
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget (2016) 0.75
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel) (2016) 0.75
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology (2016) 0.75
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period? Curr Anesthesiol Rep (2015) 0.75
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat (2017) 0.75
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget (2017) 0.75
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast (2014) 2.05
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol (2016) 0.75